- In August 2024, DePuy Synthes, part of Johnson & Johnson MedTech, launched the MatrixSTERNUM Fixation System. This system is designed to stabilize the chest wall following open-heart and chest surgeries, offering enhanced locking strength and expedited chest fixation
- In May 2024, Abbott Laboratories introduced the XIENCE Sierra Everolimus Eluting Coronary Stent System in India. This device features an upgraded stent design and an innovative delivery mechanism, aimed at assisting healthcare professionals in addressing complex cardiac cases
- In October 2023, SS Innovations International, Inc. launched an inventive robotic cardiac surgery program in India. This program utilizes the company's flagship SSi Mantra surgical robotic system, aiming to lower the cost of robotic surgery and increase its accessibility
- In October 2022, The U.S. FDA has given Medtronic plc permission for extended labeling of a cardiac lead that uses the heart's natural electrical circuitry to deliver essential treatment while avoiding problems such as cardiomyopathy frequently associated with conventional pacing techniques
- In October 2022, The HELIOSTAR Balloon Ablation Catheter was introduced in Europe by Biosense Webster, Inc., a Johnson & Johnson MedTech subsidiary. When used with a suitable multi-channel RF generator, the HELIOSTAR Balloon Ablation Catheter is approved for cardiac ablation and catheter-based cardiac electrophysiological mapping (stimulating and recording) of the atria
Frequently Asked Questions
Asia-Pacific is the fastest growing region in the global cardiac surgery instruments market due to state-of-the-art hospitals and surgical centers, ensuring the availability and adoption of cutting-edge cardiac surgical instruments.
The surge in minimally invasive cardiac surgeries, is emerging as a pivotal trend driving the global cardiac surgery instruments market.
The major factors driving the growth of the cardiac surgery instruments market are growing need due to increasing prevalence of cardiovascular disease
The primary challenges include high cost of advanced surgical instruments and competitive market dynamics challenging brand differentiation.
The forceps segment is expected to dominate the global cardiac surgery instruments market holding a major market share in 2025, attributed to their frequent use in various procedures, Includes vascular, grasping, and other specialized forceps, catering to diverse surgical needs.
